Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 10/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 7/20 | 0.55 |
| ▸ | GRPR | P30550 | 1/20 | 0.54 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064553 | 0.97 | GLP1R (0.58) | GLP1RIL23RGRPR | |
| SCHEMBL30932144 | 0.95 | GLP1R (0.59) | GLP1R | |
| SCHEMBL29613390 | 0.93 | IL23R (0.55) | GLP1RIL23RGRPR | |
| SCHEMBL30932143 | 0.93 | GLP1R (0.60) | GLP1R | |
| SCHEMBL30063985 | 0.93 | GLP1R (0.54) | GLP1RIL23RGRPR | |
| SCHEMBL30183034 | 0.92 | GLP1R (0.55) | GLP1RIL23RGRPR | |
| SCHEMBL29484310 | 0.92 | CTSL (0.53) | GLP1RIL23RGRPR | |
| SCHEMBL30063158 | 0.90 | GLP1R (0.57) | GLP1R | |
| SCHEMBL29740501 | 0.90 | GLP1R (0.59) | GLP1RIL23R | |
| SCHEMBL30496771 | 0.90 | CTSL (0.50) | GLP1RIL23RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069653-A1 | COMPLEMENT INHIBITOR DOSING REGIMENS | APELLIS PHARMACEUTICALS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12528836-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12458695-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3524258-B1 | METHODS OF TREATING CHRONIC DISORDERS WITH COMPLEMENT INHIBITORS | APELLIS PHARMACEUTICALS INC (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250282823-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4585228-A2 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | Apellis Pharmaceuticals, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250170209-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250170210-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250145673-A1 | POLYPEPTIDES FOR COMPLEMENT INHIBITION | AFFILOGIC (FR) | 2025-05-08 | — | — | US | disclosed |
| US-20220249663-A1 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT AND TREATMENT SELECTION | APELLIS PHARMACEUTICALS, INC. | 2022-08-11 | — | — | US | disclosed |
| US-20220249706-A1 | VIRAL VECTOR THERAPY | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3660033-B9 | LONG-ACTING COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11338013-B2 | Combination therapy for C3 inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-105582523-B | Compstatin and analogs thereof for ocular disorders | 阿佩利斯制药公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-2707384-B1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11292815-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11291407-B2 | Detection of high risk drusen | APELLIS PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| WO-2022061304-A1 | METHODS OF TREATING EYE DISORDERS | APELLIS PHARMACEUTICALS, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291407-B2 | Detection of high risk drusen | EXOSC4, EXOSC5, EXOSC10 | GLP1R 1394/4885IL23R 3717/4885GRPR 2579/4885 |
| US-20250170209-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | GLP1R 392/4885IL23R 1502/4885GRPR 495/4885 |
| US-12458695-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | GLP1R 392/4885IL23R 1502/4885GRPR 495/4885 |
| US-20250170210-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | GLP1R 392/4885IL23R 1502/4885GRPR 495/4885 |
| US-20250282823-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | GLP1R 279/4885IL23R 1100/4885GRPR 377/4885 |
| US-12528836-B2 | Dosing regimens | CFD, CFB, VIP | GLP1R 320/4885IL23R 859/4885GRPR 357/4885 |
| US-11292815-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | ANPEP, ADAM8, MSTN | GLP1R 426/4885IL23R 1017/4885GRPR 256/4885 |
| US-11338013-B2 | Combination therapy for C3 inhibition | C3AR1, C5, CFH | GLP1R 898/4885IL23R 1076/4885GRPR 965/4885 |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | MASP2, CLEC4M, C1QBP | GLP1R 1096/4885IL23R 1483/4885GRPR 1638/4885 |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | C9, C3AR1, SERPINC1 | GLP1R 1105/4885IL23R 2240/4885GRPR 526/4885 |
| US-20220249706-A1 | VIRAL VECTOR THERAPY | CFH, CFB, HAVCR2 | GLP1R 4825/4885IL23R 976/4885GRPR 3951/4885 |
| US-20260069653-A1 | COMPLEMENT INHIBITOR DOSING REGIMENS | CFD, C5, C1QBP | GLP1R 1321/4885IL23R 968/4885GRPR 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.